| SERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCE |
SALT LAKE CITY , May 14, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the RBC Global Healthcare Conference on Wednesday, May 21, 2025, from 9:30 – 9:55 a.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss the company's latest achievements. |
prnewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Down -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a Turnaround |
Sera Prognostics (SERA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-05-13 14:35:24 |
Czytaj oryginał (ang.) |
| Sera Prognostics Inc (SERA) Q1 2025 Earnings Call Transcript |
Sera Prognostics Inc (NASDAQ:SERA ) Q1 2025 Earnings Conference Call May 7, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Zhenya Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen. Operator Good afternoon and welcome to the Sera Prognostics Conference Call to review First Quarter Fiscal Year 2025 Results. |
seekingalpha.com |
2025-05-11 09:35:21 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICER |
Industry Veteran to Spearhead Commercial Expansion, Driving Innovation and Growth at the Company SALT LAKE CITY , May 8, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the appointment of Lee Anderson as Chief Commercial Officer. Bringing more than 30 years of cross-functional leadership experience in sales, marketing, customer service, strategic accounts, and training, Mr. |
prnewswire.com |
2025-05-08 20:40:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates |
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2025-05-07 23:00:59 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS |
SALT LAKE CITY , May 7, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2025 ended March 31, 2025. Recent Highlights: Following release of full Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study results meeting primary success criteria, Sera is elevating engagement with payors and plan administrators. |
prnewswire.com |
2025-05-07 20:05:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2025 Financial Results on May 7, 2025 |
SALT LAKE CITY , April 24, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2025 financial results on Wednesday, May 7, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. |
prnewswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript |
Sera Prognostics Inc (NASDAQ:SERA ) Q4 2024 Earnings Conference Call March 19, 2025 5:00 PM ET Company Participants Peter DeNardo - IR, CapComm Partners Evguenia Lindgardt - President, CEO & Director Austin Aerts - CFO Conference Call Participants Dan Brennan - TD Cowen Margarate Boeye - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Fourth Quarter Fiscal Year 2024 Results. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-03-19 21:13:13 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Misses Revenue Estimates |
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.25 per share a year ago. |
zacks.com |
2025-03-19 20:20:17 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN |
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its shareholders—has informed the Company of his intention to retire and step down as a director effective June 30, 2025 as part of the Board's ongoing efforts to refresh its composition, expertise and experience. |
prnewswire.com |
2025-03-19 18:10:00 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS REPORTS FOURTH QUARTER 2024 FINANCIAL RESULTS |
SALT LAKE CITY , March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: On January 6, 2025, the Society for Maternal Fetal Medicine ("SMFM") published an abstract reporting topline results for Sera's Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs ("PRIME") study. |
prnewswire.com |
2025-03-19 18:05:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Conference Call and Webcast of Fourth Quarter and Fiscal Year 2024 Financial Results on March 19, 2025 |
SALT LAKE CITY , March 11, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, March 19, 2025, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. |
prnewswire.com |
2025-03-11 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics To Present at TD Cowen 45th Annual Health Care Conference |
SALT LAKE CITY , Feb. 21, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 9:50 a.m. – 10:20 a.m. |
prnewswire.com |
2025-02-21 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Pricing of $50 Million Public Offering |
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the pricing of its underwritten public offering of 1,250,000 shares of its Class A common stock at a public offering price of $4.00 per share, and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase 11,250,000 shares of its Class A common stock at a public offering price of $3.9999 per pre-funded warrant, which equals the public offering price per share of the Class A common stock less the $0.0001 per share exercise price of each pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sera, are expected to be approximately $50 million. |
prnewswire.com |
2025-02-11 00:41:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Proposed Public Offering |
SALT LAKE CITY , Feb. 10, 2025 /PRNewswire/ -- Sera Prognostics, Inc., The Pregnancy Company® ("Sera" or the "Company") (Nasdaq: SERA), which focuses on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase shares of its Class A common stock. In addition, Sera intends to grant the underwriters a 30-day option to purchase shares of Class A common stock in an amount up to an additional 15% of the total amount of shares of Class A common stock and shares of Class A common stock underlying pre-funded warrants sold in the public offering on the same terms and conditions. |
prnewswire.com |
2025-02-10 18:01:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Host Virtual R&D Day on January 31 |
Event will showcase results of Company's pivotal PRIME study and include the principal investigator SALT LAKE CITY , Jan. 27, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it plans to host a virtual R&D day on January 31, 2025, from 5:00 to 6:00 p.m. ET/2:00 to 3:00 p.m. |
prnewswire.com |
2025-01-27 19:02:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Present at 43rd Annual J.P. Morgan Healthcare Conference |
SALT LAKE CITY , Jan. 6, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025 in San Francisco. |
prnewswire.com |
2025-01-06 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Present PRIME Study Results at 2025 SMFM Pregnancy Meeting |
SALT LAKE CITY , Dec. 4, 2024 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the results of the PRIME study were accepted as a late-breaking abstract for oral podium presentation at the Society for Maternal-Fetal Medicine 2025 Pregnancy Meeting™ on January 31, 2025 at 10:15 a.m. MT . Dr. Brian Iriye – maternal-fetal medicine expert at the High Risk Pregnancy Center in Las Vegas, Nevada, and principal investigator for the PRIME study – will present the results of the full PRIME study. |
prnewswire.com |
2024-12-04 18:01:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Present at Piper Sandler 36th Annual Healthcare Conference |
SALT LAKE CITY , Dec. 2, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Piper Sandler 36th Annual Healthcare Conference on December 5, 2024 at 2:30 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. |
prnewswire.com |
2024-12-02 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum |
SALT LAKE CITY , Nov. 15, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21, 2024 at 4:00 p.m. ET. Zhenya Lindgardt, President and CEO, will participate in a fireside chat and provide a company update and discuss Sera's latest achievements. |
prnewswire.com |
2024-11-15 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript |
Sera Prognostics Inc (NASDAQ:SERA ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Peter DeNardo - IR Evguenia Lindgardt - President, CEO & Director Austin Aerts - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review Third Quarter Fiscal Year 2024 Results. [Operator Instructions] As a reminder, the call is being recorded for replay purposes. |
seekingalpha.com |
2024-11-07 11:46:05 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Reports Q3 Loss, Lags Revenue Estimates |
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. |
zacks.com |
2024-11-06 21:00:43 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS |
SALT LAKE CITY , Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the third quarter of 2024 ended September 30, 2024. Recent Highlights: Data analysis for full Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study underway after database was locked in September and now seeking publication of results in connection with key pregnancy and maternal health conferences in early 2025 and manuscript submission to a quality peer-reviewed journal. |
prnewswire.com |
2024-11-06 18:05:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Conference Call and Webcast of Third Quarter Fiscal Year 2024 Financial Results on November 6, 2024 |
SALT LAKE CITY , Oct. 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report third quarter fiscal year 2024 financial results on Wednesday, November 6, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. |
prnewswire.com |
2024-10-28 10:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Present at H.C. Wainwright 26th Annual Global Investment Conference |
SALT LAKE CITY , Sept. 4, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. |
prnewswire.com |
2024-09-04 20:53:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Q2 2024 Earnings Call Transcript |
Sera Prognostics, Inc. (NASDAQ:SERA ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & CEO Austin Aerts - CFO Conference Call Participants Andrew Brackmann - William Blair Dan Brennan - TD Cowen Operator Good afternoon, and welcome to the Sera Prognostics Conference Call to review second quarter fiscal year 2024 results. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. |
seekingalpha.com |
2024-08-09 21:28:16 |
Czytaj oryginał (ang.) |
| Sera Prognostics to Participate in Panel Discussion at UBS Genomic Medicine Summit on August 14, 2024 |
SALT LAKE CITY , Aug. 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that its management team will participate in the following upcoming investor conference: UBS Genomic Medicine Summit, August 13-14. President and Chief Executive Officer, Zhenya Lindgardt, will participate in a panel discussion: Future of Genetic Testing – Babies and Beyond, on August 14 at 8:00 a.m. |
prnewswire.com |
2024-08-08 12:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates |
Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.34 per share a year ago. |
zacks.com |
2024-08-07 22:50:41 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS |
SALT LAKE CITY , Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc. , The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the second quarter of 2024 ended June 30, 2024. Recent Highlights: Publication of positive AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls) results in international peer-reviewed journal, Diagnostics , with coverage on front page of publication. |
prnewswire.com |
2024-08-07 20:05:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2024 Financial Results on August 7, 2024 |
SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report second quarter fiscal year 2024 financial results on Wednesday, August 7, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. |
prnewswire.com |
2024-07-25 12:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics PreTRM® Test Prevention Strategy Demonstrates 18% Reduction in Severe Neonatal Morbidity and Mortality in Newly Published AVERT Trial |
Sera Prognostics Announces Publication of Positive AVERT PRETERM TRIAL Results in the International Peer-Reviewed Journal, Diagnostics SALT LAKE CITY , July 9, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced the publication in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis, of the top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. PreTRM® test-and-treat strategy demonstrates statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay Previously, Sera reported that both co-primary outcomes—reduction of severe neonatal morbidity or neonatal death; and decreased length of neonatal hospital stay—met their endpoints, and the improvements in outcome with a PreTRM® test-and-treat approach were statistically significant. |
prnewswire.com |
2024-07-09 12:30:00 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS ADDED TO RUSSELL 2000 AND 3000 INDEXES FOLLOWING CONCLUSION OF 2024 INDEXES ANNUAL RECONSTITUTION |
SALT LAKE CITY , July 1, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that as a result of the annual Russell Reconstitution being finalized on June 28, 2024, the Company has been added to the Russell Small-Cap 2000 and Russell 3000 indexes effective with the opening of equity markets today. The annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30 th, 2024, ranking them by total market capitalization. |
prnewswire.com |
2024-07-01 12:30:00 |
Czytaj oryginał (ang.) |
| 3 Stocks Under $10 With the Potential to Make You a Millionaire |
Buying stocks that can make you millions is any investor's dream. That is why some investors consider micro-cap or small-cap stocks trading under $10. |
investorplace.com |
2024-06-16 10:17:00 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS EXPECTED TO BE ADDED TO RUSSELL 2000 AND 3000 INDEXES |
SALT LAKE CITY , May 28, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it has been added to the preliminary list of the Russell Small-Cap 2000 and Russell 3000 indexes as part of the Russell indexes annual reconstitution. "We are pleased to be included in the preliminary list of the Russell 3000 Index, as it marks another step forward for Sera during a year in which we expect to achieve several milestones in advancing our role as 'The pregnancy company' to improve maternal and neonatal healthcare outcomes," said Zhenya Lindgardt, President and CEO of Sera Prognostics. |
prnewswire.com |
2024-05-28 12:30:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics, Inc. (SERA) Q1 2024 Earnings Call Transcript |
Sera Prognostics, Inc. (NASDAQ:SERA ) Q1 2024 Earnings Conference Call May 8, 2024 5:00 PM ET Company Participants Peter DeNardo - CapComm Partners Zhenya Lindgardt - President & Chief Executive Officer Austin Aerts - Chief Financial Officer Conference Call Participants Operator Good afternoon and welcome to the Sera Prognostics Conference Call to Review First Quarter Fiscal Year 2024 Results. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-09 03:10:23 |
Czytaj oryginał (ang.) |
| SERA PROGNOSTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS |
SALT LAKE CITY , May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter of 2024 ended March 31, 2024. Recent Highlights: Submitted manuscript of PRIME study interim analysis results for peer-reviewed publication. |
prnewswire.com |
2024-05-08 20:05:00 |
Czytaj oryginał (ang.) |
| Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2024 Financial Results on May 8, 2024 |
SALT LAKE CITY , April 29, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that it will report first quarter fiscal year 2024 financial results on Wednesday, May 8, 2024, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m. |
prnewswire.com |
2024-04-29 18:15:00 |
Czytaj oryginał (ang.) |